Eli Lilly and Co (MIC:LLY-RM) Piotroski F-Score: 8 (As of Jun. 28, 2026) — 33% Above Median


What is Eli Lilly and Co Piotroski F-Score?

Eli Lilly and Co MIC:LLY-RM 98 Piotroski F-Score is 8 as of Jun. 28, 2026, which is 33% above its 10-year median of 6.00. GuruFocus rates MIC:LLY-RM with a GF Score™ of 98/100. The stock has 6 warning signs investors should review. Among 978 Drug Manufacturers companies, Eli Lilly and Co ranks better than 98.36% on this metric.

Good Sign:

Piotroski F-Score is 8, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Eli Lilly and Co has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Eli Lilly and Co's Piotroski F-Score or its related term are showing as below:

MIC:LLY-RM' s Piotroski F-Score Range Over the Past 10 Years
Min: 4   Med: 6   Max: 8
Current: 8

During the past 13 years, the highest Piotroski F-Score of Eli Lilly and Co was 8. The lowest was 4. And the median was 6.

Eli Lilly and Co  (MIC:LLY-RM) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Eli Lilly and Co Piotroski F-Score Related Terms


Eli Lilly and Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Eli Lilly and Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co Piotroski F-Score Chart

Eli Lilly and Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.00 7.00 5.00 7.00 7.00

Eli Lilly and Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.00 7.00 7.00 7.00 8.00

MIC:LLY-RM vs JNJ, ABBV, MRK: Piotroski F-Score Comparison

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 439977.124 + 463735.251 + 527671.932 + 601213.456 = ₽2,032,597.76 Mil.
Cash Flow from Operations was 239906.262 + 733993.427 + 256343.449 + 433514.246 = ₽1,663,757.38 Mil.
Revenue was 1209262.805 + 1462088.923 + 1533640.705 + 1609440.944 = ₽5,814,433.38 Mil.
Gross Profit was 1019001.167 + 1212191.071 + 1265603.365 + 1318670.185 = ₽4,815,465.79 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(7385279.698 + 7844472.28 + 9547621.424 + 8941414.679 + 9476346.656) / 5 = ₽8639026.9474 Mil.
Total Assets at the begining of this year (Mar25) was ₽7,385,279.70 Mil.
Long-Term Debt & Capital Lease Obligation was ₽3,200,348.00 Mil.
Total Current Assets was ₽4,457,482.41 Mil.
Total Current Liabilities was ₽2,977,941.29 Mil.
Net Income was 268216.805 + 87933.437 + 474498.881 + 227947.871 = ₽1,058,596.99 Mil.

Revenue was 1021773.139 + 1036668.434 + 1456175.066 + 1051666.711 = ₽4,566,283.35 Mil.
Gross Profit was 825587.055 + 839939.684 + 1197556.067 + 867837.782 = ₽3,730,920.59 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(5850894.144 + 6497482.039 + 6851875.287 + 8469812.556 + 7385279.698) / 5 = ₽7011068.7448 Mil.
Total Assets at the begining of last year (Mar24) was ₽5,850,894.14 Mil.
Long-Term Debt & Capital Lease Obligation was ₽2,850,339.83 Mil.
Total Current Assets was ₽3,408,989.75 Mil.
Total Current Liabilities was ₽2,484,218.70 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Eli Lilly and Co's current Net Income (TTM) was 2,032,597.76. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Eli Lilly and Co's current Cash Flow from Operations (TTM) was 1,663,757.38. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=2032597.763/7385279.698
=0.27522285

ROA (Last Year)=Net Income/Total Assets (Mar24)
=1058596.994/5850894.144
=0.1809291

Eli Lilly and Co's return on assets of this year was 0.27522285. Eli Lilly and Co's return on assets of last year was 0.1809291. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Eli Lilly and Co's current Net Income (TTM) was 2,032,597.76. Eli Lilly and Co's current Cash Flow from Operations (TTM) was 1,663,757.38. ==> 1,663,757.38 <= 2,032,597.76 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=3200347.995/8639026.9474
=0.37045237

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=2850339.829/7011068.7448
=0.40654855

Eli Lilly and Co's gearing of this year was 0.37045237. Eli Lilly and Co's gearing of last year was 0.40654855. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=4457482.405/2977941.286
=1.49683354

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=3408989.747/2484218.7
=1.37225831

Eli Lilly and Co's current ratio of this year was 1.49683354. Eli Lilly and Co's current ratio of last year was 1.37225831. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Eli Lilly and Co's number of shares in issue this year was 895.9. Eli Lilly and Co's number of shares in issue last year was 900.6. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=4815465.788/5814433.377
=0.82819176

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=3730920.588/4566283.35
=0.81705849

Eli Lilly and Co's gross margin of this year was 0.82819176. Eli Lilly and Co's gross margin of last year was 0.81705849. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=5814433.377/7385279.698
=0.78730036

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=4566283.35/5850894.144
=0.78044197

Eli Lilly and Co's asset turnover of this year was 0.78730036. Eli Lilly and Co's asset turnover of last year was 0.78044197. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+0+1+1+1+1+1
=8

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Eli Lilly and Co has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 8 mean?
Eli Lilly and Co (MIC:LLY-RM) has a Piotroski F-Score of 8 as of Jun. 28, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Eli Lilly and Co and its competitors. This is 33% above median its historical median of 6.00. Over the past decade, Eli Lilly and Co's Piotroski F-Score has ranged from 4.00 to 8.00. According to the industry distribution chart, Eli Lilly and Co ranks #16 out of 978 companies in the Drug Manufacturers industry, placing it in the top 1.6%.
Is Eli Lilly and Co's Piotroski F-Score too high?
Eli Lilly and Co's current Piotroski F-Score of 8 is 33% above median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 8.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Eli Lilly and Co's value of 8 is 60% above this industry median. Based on the distribution chart, Eli Lilly and Co ranks #16 out of 978 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Eli Lilly and Co has a GF Score™ of 98/100, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's Piotroski F-Score compare to JNJ and ABBV?
According to the Drug Manufacturers industry distribution chart, Eli Lilly and Co ranks #16 out of 978 companies for Piotroski F-Score. This places Eli Lilly and Co in the top 2% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Eli Lilly and Co's value of 8 is 60% above this benchmark. Historically, Eli Lilly and Co's own Piotroski F-Score has ranged from 4.00 to 8.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Eli Lilly and Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 978 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eli Lilly and Co's current Piotroski F-Score of 8 is 60% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Eli Lilly and Co and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eli Lilly and Co's current Piotroski F-Score is 8, which is 33% above median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Eli Lilly and Co (MIC:LLY-RM) has a current Piotroski F-Score of 8. The current Piotroski F-Score is 8, which is 33% above median its 10-year median of 6.00 and 60% above the Drug Manufacturers industry median of 5.00. Eli Lilly and Co's overall GF Score™ is 98/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Eli Lilly and Co (MIC:LLY-RM), the current Piotroski F-Score is 8 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.